PARI licenses advanced vaporizing technology

Monday, February 28, 2005

MIDLOTHIAN, Va. - PARI Innovative Manufacturers has licensed a novel capillary force vaporizer technology that quickly converts liquid to vapor. PARI expects the technology, manufactured by Vapore, to drastically change current respiratory devices, such as humidifiers that generate water vapor. While standard humidifiers take 20-30 minutes to begin producing vapor, the D battery-sized ceramic device generates vapor in 2-3 seconds. Pari anticipates use of the technology for treatments in respiratory care, humidification, smoking cessation and infant incubators.
Otto Bock Healthcare acquires OrthoRehab
MINNEAPOLIS, Minn. - OttoBock Healthcare last month announced the acquisition of OrthoRehab. The deal combines complementary rehabilitation product lines, corporate cultures and sales strategies to fuel future growth in the North American rehabilitation market, according to a company release. OrthoRehab, headquartered in Tempe, Ariz., employs 260 people and serves patients recovering from major orthopedic surgery. OrthoRehab’s products utilize continuous passive motion, TENS, NMES and cold therapies to speed recovery. “Acquiring OrthoRehab is a key strategic step in our growth plans for the U.S. rehabilitation market,” said Bert Harman, president and CEO of Otto Bock North America. “OrthoRehab’s sales force will be able to broaden their portfolio while providing a new channel for existing Otto Bock products. We are excited about the growth potential inherent in this deal.”
ResMed posts more eye-opening gains
SAN DIEGO - ResMed’s share price soared 14% early last month after the company reported a 26% boost in sales and a 27% increase in profits over last year. The company posted $104 million in sales for the quarter,thanks in part to strong demand for the company’s new Mirage Swift patient interface. ResMed is forecasting 15-20% growth over the next 12-18 months. “Even as we continue to grow in our key markets throughout the world, most remain under penetrated and patients remain under served,” said Peter Farrell, ResMed CEO.